ArticleScientific reports2026
Novel fatty acid metabolism risk score model for guiding treatment in endometrial endometrioid cancer.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Endometrial cancer ranks among the most prevalent tumours in women, with approximately 80-85% classified as endometrioid type. Evidence has suggested a significant link between obesity and the development of endometrial endometrioid cancer (EEC). We analysed RNA sequencing data encompassing 407 EEC samples and 35 normal endometrial tissue samples sourced from TCGA, and created a risk score model built on differentially expressed genes related to fatty acid metabolism within the tumour microenvironment (TME). Patients categorised as high-risk scores exhibited a higher prevalence of dMMR and TP53 mutations, fewer mutations in KRAS and PTEN, and worse prognostic outcomes. Further investigation indicated that the two patient subgroups showed varying sensitivities to different chemotherapeutic agents. Additionally, the composition of immune cell infiltration in the TME diverged between these subgroups. Tumour Immune Dysfunction and Exclusion analysis suggested that individuals with high-risk scores are not suited for immunotherapeutic intervention. Based on bioinformatic analyses, this research offers a novel framework for the classification and therapeutic direction of EEC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.